SCHEMBL13045595

SCHEMBL13045595

NC1CC(C(=O)O)OC1=O

nearest known ligand 0.36

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
ABAT P80404 1/20 0.33
OAT P04181 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063270 0.76 SMN1; SMN2 (0.35) SMN1; SMN2
SCHEMBL9218081 0.74 SMN1; SMN2 (0.34) SMN1; SMN2
SCHEMBL9745576 0.74 SMN1; SMN2 (0.34) SMN1; SMN2
SCHEMBL13758784 0.72 IDUA (0.36) SMN1; SMN2
SCHEMBL17678526 0.72 IDUA (0.36) SMN1; SMN2
SCHEMBL2806987 0.69 POLB (0.43) SMN1; SMN2
SCHEMBL188282 0.69 SMN1; SMN2 (0.32) SMN1; SMN2
SCHEMBL3530476 0.69 SIRT1 (0.41) SMN1; SMN2
SCHEMBL2804445 0.67 CYP2C9 (0.48) SMN1; SMN2
SCHEMBL3183082 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834033-B2 Methods for treating cancer using 3-[1,3dioxo-4-benzamidoisoindolin-2-yl]-2,6-dioxo-5-hydroxypiperidine CELGENE CORPORATION (US) 2010-11-16 US disclosed
US-7834033-B2 Methods for treating cancer using 3-[1,3dioxo-4-benzamidoisoindolin-2-yl]-2,6-dioxo-5-hydroxypiperidine CELGENE CORPORATION (US) 2010-11-16 US disclosed
EP-1733726-B1 Pharmaceutically active isoindoline derivatives CELGENE CORP (US) 2009-06-03 EP disclosed
EP-1341537-B1 PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES CELGENE CORP (US) 2007-01-24 EP disclosed